MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze ROIV →
    • FindStock Picks / Stock Screener
    • Value · ROIVIntrinsic Value Calculator
    • Invest · ROIVInvestment Case
    • Hold · ROIV5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ROIV stock logo

ROIV

Roivant Sciences Ltd.

$38.66
-0.31
 (-0.78%)
Exchange:  NASDAQ
Market Cap:  28.008B
Shares Outstanding:  693.865M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Matthew Gline
Full Time Employees:  721
Address: 
50 Broadway
London
GL
SW1H 0DB
GB
Website:  https://roivant.com
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm’s development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Click to read more…

Revenue Segmentation

Revenue by type

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

ROIV full analysis

26/11/2025

Welcome to MARKETSNAP’s SWOT analysis for Roivant Sciences Ltd., a company that might not be on everyone’s radar but is definitely worth a deep dive for long-term investors like us. If you’re looking to build wealth over time with smart picks, let’s unpack what makes this biotech player tick, where it’s shining, where it’s stumbling, and what could shape its future. Stick with me as we break down the strengths, weaknesses, opportunities, and threats for Roivant Sciences, along with some…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ROROIV logoROIVRoivant Sciences Ltd.28.0B——-11.8%
ININSM logoINSMInsmed Incorporated31.0B——-32.8%
GMGMAB logoGMABGenmab A/S31.2B42.940.210.3%
UTUTHR logoUTHRUnited Therapeutics Corporation23.6B19.422.516.8%
ININCY logoINCYIncyte Corporation23.4B54.636.26.0%
RVRVMD logoRVMDRevolution Medicines, Inc.34.9B——-43.9%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/09 — 2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue32,71329,0538,260
Gross Profit31,11428,1426,975
EBITDA4,624,670-667,519-261,230
Operating Income4,497,032-1,003,294-515,068
Net Income4,348,926-171,981-299,771

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets7,222,4825,436,9405,708,687
Total Liabilities773,953249,742416,275
Total Stockholders Equity5,968,5814,687,6054,527,370
Total Debt499,749100,170107,438
Cash and Cash Equivalents6,535,7062,715,4111,419,232

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-765,268-839,451-750,349
Capital Expenditure-1,382-4,599-8,209
Free Cash Flow-766,650-844,050-758,558
Net Income4,231,206-356,734-397,907
Net Change in Cash4,858,335-3,824,789-1,294,679

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)3,261,907.709Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)7,912,674.467Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)5,609,623Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)1,839,152.335Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)4,415,202.225Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)3,139,544.764Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)897,812.132Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)3,020,184.144Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,969,187.538Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)86,873,243.711Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)210,735,483.251Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)149,399,121.459Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.840Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.350Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)1.290Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)4Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
124.795M  ?P/S
 (TTM)
: 
681.76
?Net Income
 (TTM)
: 
4.349B  ?P/E
 (TTM)
: 
-80.53
?Enterprise Value
 (TTM)
: 
26.472B  ?EV/FCF
 (TTM)
: 
-793.98
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-8.08%  ?ROIC
 (TTM)
: 
-11.85%
?Net Debt
 (TTM)
: 
-5.049B  ?Debt/Equity
 (TTM)
: 
0.03
?P/B
 (TTM)
: 
6.95  ?Current Ratio
 (TTM)
: 
15.56

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Strong Cash Position: As highlighted in the Q3 2024 earnings call, Roivant Sciences Ltd. maintains a robust cash reserve of $5 billion, providing significant financial flexibility for R&D investments, acquisitions, and operational needs.
  • Positive Financial Performance: Key financial results from the earnings call indicate revenue growth and improved profitability metrics, positioning ROIV favorably against industry benchmarks in the biotechnology sector.
  • Innovative Pipeline: The earnings call emphasized advancements in clinical programs, with promising early-stage results that could drive future revenue streams if successfully commercialized.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates ROIV intrinsic value between $35.28 – $42.56 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ROIV Intrinsic Value

Common questions about ROIV valuation

Is Roivant Sciences Ltd. (ROIV) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Roivant Sciences Ltd. (ROIV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ROIV a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ROIV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ROIV’s P/E ratio?

You can see ROIV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ROIV?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ROIV a good long-term investment?

Whether ROIV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Roivant Sciences Ltd.

  • Roivant Sciences Ltd. intrinsic value calculatorEstimate what the business is worth
  • Roivant Sciences Ltd. 5-year outlookWhat has to go right, and what could go wrong
ROIV

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.78
MarketSnap

Trading Metrics:

Open: 38.86   Previous Close: 38.96
Day Low: 38.46   Day High: 39.51
Year Low: 19.96   Year High: 42.5
Price Avg 50: 37.22   Price Avg 200: 32.65
Volume: 3.97M   Average Volume: 7.349M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
20-11-2026 13:01
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
126,491 Shares in Roivant Sciences Ltd. $ROIV Bought by Edgestream Partners L.P.
20-11-2026 04:46
126,491 Shares in Roivant Sciences Ltd. $ROIV Bought by Edgestream Partners L.P.
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
10-11-2026 13:24
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
28-09-2026 04:02
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
22-09-2026 14:29
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
10-09-2026 17:07
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze ROIV →
    • FindStock Picks / Stock Screener
    • Value · ROIVIntrinsic Value Calculator
    • Invest · ROIVInvestment Case
    • Hold · ROIV5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.